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A B S T R A C THealth state utility values (HSUVs) are important parameters in
decision models in health technology assessment submissions.
Reimbursement agencies, such as the National Institute for Health
and Clinical Excellence, recognize that such values are obtainable
from the published literature. However, to use published values in
health technology assessment submissions, it should be demon-
strated that HSUVs have been identiﬁed and selected systemati-
cally to avoid using biased HSUVs resulting in cost-effectiveness
analyses. This article presents guidance on how to conduct a
systematic literature review to identify and select HSUVs from
the published literature based on the authors’ experience. A case
study is used to demonstrate some of the features of a systematicsee front matter Copyright & 2013, International S
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eld S1 4DA, UK.HSUV review. Methods are discussed in relation to identifying and
selecting the evidence, performing quality and relevance assess-
ment, and undertaking data extraction. It has been developed from
a Technical Support Document produced for the National Institute
for Health and Clinical Excellence by the Decision Support Unit
at the School of Health and Related Research, University of
Shefﬁeld.
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There is little guidance in texts for health economic evaluation [1,2]
on how to identify health state utility value (HSUV) evidence system-
atically for the health states used in decision models to estimate
incremental cost-effectiveness. Decision models often present a
single set of HSUVs to inform such parameters, with little justiﬁca-
tion as to why they have been selected above other values [3].
Obtaining an unbiased selection of studies is an essential
component of any systematic review. Methods for identifying
evidence for systematic reviews undertaken to generate reliable
estimates of clinical effects for use in decision models are well
developed [4,5]. With a growing literature of empirically derived
HSUVs, it is increasingly important to ensure that the methods
used to identify and select HUSVs are systematic and transparent
to justify the values that are used in decision models. Biased
HSUVs will result in biased cost-effectiveness analyses and
potential misallocation of resources.
In 2008, Brazier [6] argued that parameter values for decision-
analytic models should be obtained from a systematic review of
the literature, akin to that of a review of clinical evidence, thus
requiring thorough searching by using appropriate terms and the
main databases. Brazier [6] also noted that systemically review-
ing the published literature might be different with regard to the
conventional hierarchy of evidence for clinical reviews. A reviewof economic models submitted to the National Institute for
Health and Clinical Excellence (NICE) as part of a technology
appraisal found that only 12 out of 71 submissions (17%) identi-
ﬁed HSUVs from a systematic review [3]. Methods on systematic
searching and selection of HSUVs from the published literature,
however, were not discussed in either article. This article seeks to
address this gap.
It has been developed from a Technical Support Document
(TSD) for NICE on “The identiﬁcation, review and synthesis
of health state utility values from the literature” [7]. This
article focuses on the identiﬁcation and selection stage in a
systematic HSUV review and summarizes the issues and guid-
ance discussed in the TSD. The TSD also considered methods of
synthesis.
The authors do not know of any speciﬁc guidance on systematic
searching and selection of HSUVs from the published literature.
The TSD and this article present guidance based on experience
of the authors, who have substantial practice in searching and
reviewing for clinical and cost-effectiveness analyses.
This article will discuss how to identify and select HSUVs for
review from the published literature in a systematic way and how
to review studies containing HSUV data in terms of quality and
relevance and how to extract HSUV values.
An outline of the HSUV systematic review process is provided
in Figure 1.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
and Related Research, University of Shefﬁeld, Regent Court, 30
Fig. 1 – Reviewing HSUVs. HSUVs, health state utility values.
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The article draws on the experience of the authors and is
illustrated with a case study that was chosen as a real-life
example of a review undertaken for a NICE Technology Appraisal.
Throughout the article, the case study referred to is a systematic
review of HSUVs in osteoporosis-related conditions [8]. The charac-
teristics of this review are described in Table 1. The osteoporosis
review was chosen as a good example that demonstrates the
problems of systematically reviewing published HSUVs. The authors
were well informed on the case study (one of the authors was
involved in this study). In addition, the review was used to provide
HSUVs for a cost-effectiveness model in a submission to NICE.
Scoping the Review
The aim at the scoping stage is to characterize the precise HSUVs
that need to be captured by the review so as to inform the decision
model. We recommend when scoping reviews of HSUVs to deﬁne
the speciﬁc health states required for the decision model and the
type of HSUV data required by the reimbursement agency Box 1.While in reviews of clinical effects, methods guides recom-
mend structuring the review question according to the Patient,
Intervention, Comparison, and Outcome (PICO) question [4,5],
this is not a useful framework for scoping HSUV reviews. First,
the “Intervention” and “Comparison” elements in PICO are not
usually relevant to HSUVs’ reviews, where the aim is often to
identify HSUV data for particular health states that are not
necessarily attached to an intervention. Second, decision models
typically require a series of HSUVs as they examine the whole
treatment pathway and thus what happens to patients over a
longer time horizon (e.g., rest of the patient’s life). For example,
over a period of treatment, HSUVs may be required for receiving
effective treatment, receiving noneffective treatment, each indi-
vidual adverse event, disease progression, or stable disease.
Third, while reviews of clinical effects often focus on speciﬁc
study designs (with evidence from randomized controlled trials
[RCTs] often being seen as the gold standard by which to assess
clinical efﬁcacy) [4,5], HSUV data are not exclusively reported in
RCTs. Often, HSUVs are reported in observational studies as well
as in other cost-effectiveness studies such as health technology
assessments (HTAs) and economic evaluations, and thus limiting
by study design is not appropriate for reviews of HSUVs.
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First, determine the distinct health states for a disease or condition
pathway within the decision model that each requires HSUV data.
This may be an iterative process, with relevant health states
emerging as the model develops, and so the need for HSUV data
may increase or change. For example, a new side effect or adverse
event might be identiﬁed that requires an appropriate HSUV value.
Figure 2 presents some health states considered in the osteopo-
rosis case study that may each require an HSUV within a decision
model of osteoporosis. The case study demonstrates that there are
multiple health states to take into account in this disease area and
thus multiple HSUVs may be required in a decision model.
An additional consideration is the time horizon of the deci-
sion model. Decision models consider what happens to patients
over a period of time, and so a series of HSUVs is required to
reﬂect the changes in patients’ health states in that time. For
example, in Figure 2, we can see that HSUVs for health states
relating to fractures may be required at different time intervals
because HSUVs immediately postfracture are likely to be different
from those at 1 year postfracture.
When considering HSUVs required for health states, there may
be population subgroups that have sufﬁciently different character-
istics that require subgroup-level HSUV data, for example, different
stage of disease, presence of comorbidities, age group, or ethnic
group. For example, in Figure 2, clinically relevant subgroups for
health states in an osteoporosis decision model might be preme-
nopausal or postmenopausal women.
Data may also be required for health states that extend
beyond the health states deﬁned in the “P” of PICO of the clinical
effectiveness review in the HTA. Interventions given for one
disease may positively or negatively impact on another disease;
for example, bisphosphonates for the treatment of osteoporosis
may reduce the risk of breast cancer [12] and alveolar bone loss in
periodontal disease [13], and thus the health states “breast
cancer” and “bone loss in periodontal disease” must be included
in the decision model that necessitates HSUV data.
There may also be instances in which the speciﬁc effects of an
intervention or treatment on quality of life , for example,
particular adverse event proﬁle orsocial impact of treatment, for
example, diabetic treatment, are required. In these instances,
itmight be more appropriate to use HSUVs from the trial itself in
the model. RCTs do sometimes use a health-related quality-of-
life (HRQOL) instrument as an outcome measure.Table 1 – Key characteristics of case studies used to illus
Population
Peasgood et al. [8] Male and female adults with conditions re
osteoporosis
Other relevant articles:
[9–11]
EQ-5D, EuroQol ﬁve-dimensional; HSUVs, health state utility values; HUI
form (derived from short form 36 health form); SG, standard gambl
analogue scale.Type of HSUV Required
The type of HSUV required depends on the decision maker/
reimbursement agency and the requirements they set down.
NICE prefers submissions to use the EuroQol ﬁve-dimensional
(EQ-5D) questionnaire; other agencies have different require-
ments. The International Society for Pharmacoeconomics and
Outcomes Research provides a comparative table examining the
preferred method of HSUV elicitation (http://www.ispor.org/PEgui
delines/COMP3.asp), with most agencies restricting to a particular
instrument or method of elicitation. However, some agencies
have no such restrictions asking submission to “justify their
selection” of HSUVs (e.g., Canada).
The process of deﬁning the scope will depend on what
evidence is available to meet the agencies’ requirements. Con-
ducting a scoping search to identify what is the likely evidence
base may assist in narrowing the scope, the rationale being that if
plentiful “ﬁrst-choice” evidence is available the scope could be
narrowed with regard to the type of HSUV. For example, where
plentiful EQ-5D evidence exists for a NICE HTA submission, given
that the EQ-5D questionnaire is the preferred measure for NICE, it
may be reasonable to restrict the scope to the EQ-5D question-
naire only. Before narrowing the scope, however, it must be
certain that the available evidence is also relevant to both the
decision model and the agency, which might not be determined
without examining the full-text article, a task that goes beyond
the brief scoping search function. Narrowing the scope too early
by focusing on one speciﬁc HSUV instrument may result in no
studies being selected for the HSUV review and subsequent
repeating of the review process for other HRQOL instruments.Identifying and Selecting the Evidence
There is a lack of empirical evidence on the optimal approach for
searching for HUSV data, with the methods guidance for reviews
of clinical effects providing no guidance on searching for HUSVs
[4,5]. There is also no known validated methodological search
ﬁlter for HUSV data, unlike reviews of clinical effects where
several search ﬁlters exist for types of study design, such as RCTs.
As per reviews of clinical effectiveness, the ideal is to adopt a
sensitive approach to searching for HUSV reviews by using a
comprehensive search strategy and searching a variety of
sources (multiple electronic databases), in conjunction with sup-trate this Technical Support Document.
Health states Types of HSUVs
identiﬁed
lated to  Established
osteoporosis
 Vertebral fracture
 Hip fracture
 Wrist fracture
 Shoulder fracture
Own health: SG, TTO,
VAS
Preference-based
measures:
EQ-5D questionnaire,
SF-6D, HUI3, QWB
Bespoke vignettes
3, health utilities index 3; SF-6D, six-dimensional health state short
e; TTO, time trade-off; QWB, quality for well-being; VAS, visual
ll
l
l
l l
l
l ll
l l
l
l
l
l
l
l
l l
Fig. 2 – Identiﬁed HSUV data needs for a decision model for osteoporosis treatment and prevention. HSUV, health state utility
value.
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citation searching. There are, however, limitations to such an
approach, namely, the resource requirement to conduct a sensi-
tive search on multiple databases and then sift the result set. In
addition, conducting a sensitive search on multiple databases
may not retrieve all relevant citations. Therefore, it would be
reasonable to accept a less comprehensive main search in the
knowledge that supplementary search techniques will likely
locate the remaining evidence. The resulting search will still be
systematic.
Collection of HSUVs
Published HSUV reviews (such as the osteoporosis review [8]) or
reviews included as part of HTA submissions to NICE or other
agencies can provide HSUVs. Locating an HSUV review can be anefﬁcient way of identifying HSUVs for HTA submissions. Where a
previous systematic review is used, however, it is essential to
establish it as of excellent quality, up to date, and relevant to the
scope. This requires some quality assessment (Please see the TSD
on “The identiﬁcation, review and synthesis of health state utility
values from the literature” for guidance on assessing the quality
of HSUV reviews) [7]. Most important, you need to be satisﬁed
that the review has used systematic and transparent methods of
identifying and selecting HSUVs and there must be some assess-
ment of the currency and the relevance.
Literature Searching
Literature searching in systematic reviews of clinical effects is
extensive and involves multiple methods for study identiﬁcation.
There is an added problem that the health states that require
l l
l
l
l
l
l
l l
l
Fig. 3 – Frequently applied MEDLINE MeSH terms to HSUV
studies (based on examination of 300 records) [1]. HSUV,
health state utility value.
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Similarly, if HSUV data cannot be identiﬁed for a health state, it
might be necessary to undertake further searching for evidence
in a related condition or for HRQOL data from condition-speciﬁc
measures. Therefore, searching for HSUV reviews is likely to
involve undertaking a sequence of searches and further search-
ing as health states emerge. Keeping careful records of each
search undertaken (and selections from the search results)
makes the search process transparent.
There are three particular issues to consider when searching
for HSUVs: 1) search terms to use, 2) sensitive versus precise
searching, and 3) where to search.
Search terms
The terminology to use for the health states aspect of the
literature search should be fairly straightforward to identify. It
is important to cover all the health states required in the decision
model. To a certain extent, this may be iterative as new relevant
health states are identiﬁed and require HSUVs, new searches will
be undertaken. The terminology for HSUV terms is more prob-
lematic with two issues, namely, relevant subject headings and
relevant words appearing in titles and abstracts of records.
Subject headings. The thesauri in Medline (MeSH) and Embase
(EMTREE) provide little coverage of this topic with no available
dedicated thesauri terms for common HSUVs (EQ-5D, SF-6D, etc.).
Some terms, however, seem to be consistently applied, and HSUV
studies are typically indexed under broader concepts such as
quality of life or quality-adjusted-life-year (QALY), terms that are
not directly relevant to HSUVs. Paisley et al. [14] identiﬁed a
cross-sectional sample of 300 records from Medline, retrieved by
using HSUV-related free-text terms. The indexing terms in those
records were examined to determine the most frequently applied
MeSH heading [14], and these are listed in descending order of
frequency in Figure 3.
We reviewed the subject headings attached to the studies
included in the osteoporosis case study review. Of the 28
included studies, 24 were indexed on Medline (irrespective of
their method of identiﬁcation in the original review). Of the 24
studies, all but 1 was assigned the MeSH term “Quality of life.”
The next most frequently assigned MeSH term was “Question-
naires,” being assigned to 8 of the 24 studies; however, most of
the other MeSH terms listed in Figure 3 were not assigned to the
studies included in the osteoporosis case study, or were assigned
to 2 or 3 studies at most.
While searching using “Quality of life” or “Questionnaires” as
MeSH terms might appear to be a useful method of identifying
relevant studies, there is a trade-off to be made between sensi-
tivity and precision. Both these MeSH terms are generic, and
while their use in an electronic database search will maximize
sensitivity of the search and reduce the risk of missing relevant
records, it will also increase the size of the result set when
combined with some disease areas, within which lies a small
number of relevant studies (i.e., lower precision).
Free-text searching. Relevant free-text terms fall into three
categories. First, there are general terms (e.g., QALY and HSUV);
second, instrument-speciﬁc terms (e.g., EQ-5D and SFD-6D); and
last, terms that relate to the associated methods of elicitation (e.
g., standard gamble and time trade-off). When using free-text
terms, it is important to take into account that terms may be
referred to or spelled in different ways. This is particularly
pertinent for search terms for HRQOL instruments, which may
be referred to by their full name or abbreviated name (e.g., EQ-5D,
euroqol, euro qol, and eq5d). Figure 4 lists some free-text terms
for use in electronic database searching for HSUVs, showing theimportance of synonyms, abbreviations, and spelling variants.
Searching using free-text terms, however, relies on terms relating
to HSUVs being present within the title or abstract of studies.
Because HSUV data are often reported as secondary or tertiary
outcomes, HSUV-related terms (e.g., EQ-5D and HSUVs) may not
be mentioned in the abstracts; thus, these studies will not be
retrieved by searching in this way.
We reviewed the free-text terms attached to the studies
included in the osteoporosis case study review. Seventeen of
the 24 studies indexed on Medline included the words “Quality of
life” in the title; 5 of the remaining 7 contained “Quality of life” in
their abstracts. All but 2 of the 24 studies included free-text terms
relating to the speciﬁc quality-of-life instrument used to generate
the HSUVs in their titles or abstract.Where to search
Electronic databases. As in reviews of clinical effectiveness, the
main method of identifying studies containing HSUV data is
searching of electronic databases. As well as searching health-
related databases such as MEDLINE, EMBASE, and CENTRAL, and
conference proceedings (e.g., ISI Proceedings), there are several
specialist health economics resources that may be useful to
search. These include the following: Cost-effectiveness Analysis Registry (formerly known as the
Harvard Cost-Effectiveness Analysis database) [15] Centre for Reviews and Dissemination databases: NHS EED
and HTA [16,17]
ll
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Fig. 4 – Common free-text terms for electronic database searching for HSUVs. HSUVs, health state utility values.
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 The EQ-5D Web site [19] (and other instrument sites)
 The MAPI Institute Web site [20]
 Submissions to NICE or other health care decision agencies
 Patient-reported outcome and quality-of-life instruments
database [21]
Supplementary search techniques. Searching electronic data-
bases is just one method of identifying the evidence for a
systematic review. Reviews of clinical effects routinely identify
studies by other methods including reference list checking and
contact with experts. Literature searches to identify published
literature on HSUVs should ideally include other methods of
identifying studies, particularly given their usefulness in locating
relevant studies.The osteoporosis case study demonstrates the importance of
supplementary search techniques in the identiﬁcation of studies
in HSUV reviews. The osteoporosis review gives a full account of
where studies were identiﬁed, with 13 of the 28 studies identiﬁed
through the electronic search, accounting for less than 50%. A
further 8 articles were found by scrutinizing the reference lists of
included studies, 4 by contact with experts, and 2 from a previous
systematic review. The osteoporosis case study demonstrates the
value of supplementary methods. The extent to which there are
low levels of sensitivity in electronic searches in the identiﬁca-
tion of HSUVs within other areas of health care is not known.
Other methods of identifying studies include citation searching
and author searching. Citation searching involves taking key relevant
articles and identifying subsequent studies that have since cited the
article(s). Where it is evident that a key author exists in a ﬁeld, it may
be useful to search for further relevant publications by the author.
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For reviews of clinical effects, a sensitive approach to searching is
standard; that is, an extensive search strategy is devised that
provides a range of synonyms for every concept to be included in
the search. The emphasis is on maximizing the sensitivity of
electronic database searching so as to reduce the risk of missing
relevant records, while increasing the size of the result set. In
addition, searches for clinical effectiveness reviews are often
limited by using a validated RCT ﬁlter.
There are problems in conducting a sensitive search strategy
on electronic databases for HSUV reviews. The aforementioned
problems with nonspeciﬁc thesauri terms means that utilizing
these to make a search strategy more sensitive does not neces-
sarily mean that all relevant records will be found. In fact, our
case study demonstrates that a large proportion of references for
the two HSUVs reviews were located by means other than
electronic database searching. This was despite the fact that
often studies identiﬁed by other means (e.g., by reference list
checking) were in fact indexed on MEDLINE and thus were there
to be identiﬁed by the electronic database search. In addition,
conducting a sensitive search on electronic databases and sifting
the large result set is resource-intensive.
Ideally, if the resources are available, then use a sensitive
approach of a comprehensive search strategy replicated on multi-
ple electronic databases, in conjunction with techniques such as
citation searching and reference list checking. However, it would
be reasonable to use a less comprehensive search strategy,
perhaps achieved by using free-text terms for HRQOL instruments
and omitting nonspeciﬁc MeSH thesauri terms. Relevant citations
omitted by the main search would likely be retrieved by techni-
ques such as citation searching and reference list checking. This
approach seems to be supported by our osteoporosis case study.
A fully worked example of the search strategy to identify HSUVs
for the osteoporosis review is provided in the TSD: “The identi-
ﬁcation, review and synthesis of health state utility values from the
literature” and the appendix of this article in Supplemental
Materials found at http://dx.doi.org/doi:10.1016/j.jval.2013.02.017 [7].Selecting Studies and Inclusion/Exclusion Criteria
Selecting studies for inclusion in HSUV reviews differs from the
process used in reviews of clinical effects because of the need to
further reﬁne the scope and inclusion/exclusion criteria of the type
of HSUV data required as the evidence base emerges. As in reviews
of clinical effects, titles, abstracts, and full texts are screened against
predeﬁned inclusion and exclusion criteria. At each stage, studies
are rejected if they do not meet one or more of the eligibility criteria.
We recommend that during the study selection phase, some
preliminary data extraction be undertaken to assess the evidence
base, which can assist in further reﬁning the inclusion and
exclusion criteria according to the breadth of evidence available.
The process of making inclusion and exclusion decisions in
HSUV reviews, however, can be difﬁcult at the title and abstract
level due to the problems with the standard of reporting within
study abstracts. There is an increased risk of failing to select a
relevant study and/or increase the number of studies that require
full-text screening. Indeed, the osteoporosis review noted that 13
studies were identiﬁed by reference list checking when in fact 8 of
these studies were indexed on Medline with terms that were used
in the review’s electronic search strategy. Thus, these studies
appear to have been missed during the study selection stage.
Preliminary Data Extraction
Once studies have been identiﬁed from the literature search as
potential includes, a preliminary sift can be undertaken toremove any obviously nonrelevant records and focus on the
studies that might contain HSUVs for the required health states
in the decision model. From this initial sift, it will be possible to
get a feel for the quantity and nature of data and thus you can
start to reﬁne the scope by weighing up the characteristics of the
possible studies in order to make a choice of the studies to be
included. To do this, it is useful to undertake some preliminary
data extraction to extract the following three key details: Population or the subjects of the health state (e.g., age, sex,
and disease severity): this should reﬂect those in the model
and are the individuals who describe the health state. Details of the approach used to describe the health state: a)
vignettes or scenarios; b) generic multiattribute health state
descriptive systems, for example, the EQ-5D questionnaire
and SF-6D; or c) direct measurement by time trade-off, stand-
ard gamble, and visual analogue scale (Note if proxy values
are used). Valuation methods: Who? (e.g., general public) and How?
(HSUV elicitation technique such as time trade-off, standard
gamble, and visual analogue scale).
Based on the ﬁndings from this preliminary data extraction
stage, a picture can be built up about the nature and quantity of
evidence available, which, in turn, helps to develop inclusion and
exclusion criteria. Think of this as an exercise to describe the
evidence available in order to make decisions about where to
reﬁne the inclusion and exclusion criteria.
For HTA submissions to a reimbursement agency, it is useful
at this stage to consider whether the studies use HSUVs derived
from the preferred instrument(s) of the agency available and if so
how many studies are there, and are these studies relevant to the
health states in the decision model?
A worked example is given in relation to preliminary data
extraction in the full TSD (“The identiﬁcation, review and syn-
thesis of health state utility values from the literature”) [7] with
regard to NICE submissions and EQ-5D questionnaire data, as
well as details on how to document the search and selection
process.Quality and Relevance Assessment
Reviews of clinical effects typically involve an assessment of the
quality of included studies, often in terms of assessing the risk of
bias in relation to study design or conduct [5]. While quality
assessment is also important for HSUVs, the relevance of the
evidence providing the HSUVs and the requirements of the policy
maker looking at the decision model must be assessed.
In HSUV reviews, the quality of included studies can be
difﬁcult to assess because there are no agreed reporting stand-
ards for these types of studies. As is with quality assessment of
all types of studies, quality assessment relies on the quality of
reporting the methods used. HSUV studies do not fall into a
particular study design; simply choosing a quality assessment
checklist on the basis of the study design may not be appropriate.
Where HSUV data are secondary or tertiary outcomes (which is
often the case within trials), it is important to consider the
possible uncertainty in the HSUV results because the study may
not have been powered and designed according to nonprimary
outcomes.
Based on experience and also incorporating the approach used
in the case studies, quality assessment of HSUV studies might
usefully focus on respondent selection and recruitment, inclusion
and exclusion criteria, and a description of the background charac-
teristics of the sample population from whom values are obtained.
It is also important to examine the response rates of the measures
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where values are collected over time, for example, response rates at
baseline compared with those at follow-up. Czoski-Murray et al. [22]
found that in populations with hip fracture, those who had a full
data set (i.e., HRQOL values for all time points in the study) had a
better recovery from hip fracture than did the full study sample.
Last, it is helpful to make a note of any further potential problems
with a study and their potential impact on the validity and robust-
ness of the HSUVs. Figure 5 outlines the essential quality assess-
ment criteria and what to consider for each.
The relevance of the data to the decision model and agency to
which the model will be submitted is as important as quality
assessment. The relevance of the data to the decision model will
involve comparing the participant characteristics in the individ-
ual HSUV study and the population being modeled. For example,
our osteoporosis review identiﬁed that institutionalized adults
were excluded from studies, and thus the HSUVs from this review
could not be applied to this population in a decision model.
Assessing relevance according to the agency to which the
model is being submitted requires detail on the HSUV data-
collection methods. Figure 6 suggests some questions to askl
l
l l
l
l
l
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Fig. 5 – Key criteria to consider in quality assessmentwhen assessing the relevance of HSUV data, with the column
on the right specifying the relevance criteria in relation to NICE,
as an example. For other agencies, the requirements will differ.Data Extraction
A further quality consideration is the validity of the measure used
to estimate the HSUVs (see, for example, reviews of vision [23] and
schizophrenia [24]). A more complete data extraction (than pre-
liminary data extraction) needs to be undertaken for those studies
identiﬁed at the selection stage for inclusion in the review. The
purpose of the “full” data extraction stage is to 1) help further
inform the inclusion/exclusion of studies by weighing up the
characteristics across candidate studies; 2) identify where it may
be possible to synthesize HSUVs and identiﬁcation of factors that
need to be considered in the interpretation of a synthesized HSUV
(e.g., heterogeneity); and 3) identify the data that will inform how
HSUVs may need to be modiﬁed for use in the health states of the
decision model.l l
l
l
l
l l
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l
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Fig. 6 – Relevance assessment criteria applied to the NICE reference case. HRQOL, health-related quality of life; NICE, National
Institute for Health and Clinical Excellence; TTO, time trade-off.
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reviews, involves design of a data extraction form to predeﬁne
exactly what data to extract and should ideally be piloted to
ensure it is collecting the necessary data [4,5]. The Centre for
Reviews and Dissemination guidance outlines the types of
information to be extracted for clinical effectiveness reviews [4],
and much is relevant to data extraction in HSUV reviews. For
example, general information such as author or country of
publication; study characteristics such as inclusion/exclusion
criteria; participant characteristics such as age, sex, disease
characteristics, and study setting. Information relating to out-
comes differs because different types of data are collected and
unique/speciﬁc techniques are involved in HSUV collection.
The process of data extraction in clinical effectiveness reviews
is ideally undertaken by two independent reviewers [4,5]. More
often, however, data extraction is undertaken by one reviewer and
checked by a second reviewer. A similar method might be applied
to HSUV reviews depending on the time and resources available.
Based on experience and by examining the types of data
extracted for the case studies, a sample data extraction form is
suggested (see online appendix in Supplemental Materials found
at http://dx.doi.org/doi:10.1016/j.jval.2013.02.017). Some modiﬁca-
tions may be necessary, particularly in relation to disease-speciﬁc
information.Fig. 7 – Recommendations for undertaking HSUV reviews.
HSUV, health state utility value.Conclusions
HSUVs are important parameters in decision models, and thus
the methods to identify, review, and select appropriate values
must be considered carefully. The principles of systematic
reviewing for clinical effectiveness can inform some aspects of
how to identify and select utilities systematically, but there are
unique issues to be explored in the scoping and identiﬁcation of
evidence of HSUVs’ reviews. This article suggests guidance on
how to scope, search, select, quality and relevance assess, data
extract, and present data. The ﬁnal selection of values used in the
model needs to be justiﬁed and sensitivity analysis undertaken of
alternative possible values (Fig. 7).Acknowledgments
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